Standard BioTools to sell Microfluidics business for continued pivot.
Standard BioTools signed a deal to sell its Microfluidics segment to ARCHIMED in an effort to streamline operations. The divestiture represents a strategic move to focus on core life science tools.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed